Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults With Refractory Sarcomas Wilms Tumor and Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
The purpose of this study is to determine the objective response rate (complete response + partial response) of cabozantinib-s-malate (XL184) in children and young adults.
- IRB Number: 1705463580 (ADVL1622)
- Research Study Identifier: TX7854
- Principal Investigator: Batra Sandeep, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required